Determination of rituximab dose according to immunologic risk in ABO-incompatible kidney transplantation

Renal Failure

Volumn 34, Issue 8, 2012, Pages 974-979

  Chung, Byung Ha ^a   Hong, Yu Ah ^a   Sun, In O ^a   Piao, Shang Guo ^a   Kim, Ji Il ^a   Moon, In Sung ^a   Choi, Bum Soon ^a   Park, Cheol Whee ^a   Kim, Yong Soo ^a   Yang, Chul Woo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

ABO incompatible; Kidney transplantation; Rituximab

Indexed keywords

BASILIXIMAB; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; TACROLIMUS;

ADULT; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BLOOD GROUP ABO SYSTEM; BLOOD GROUP INCOMPATIBILITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; DESENSITIZATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; PLASMAPHERESIS; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REOPERATION; RISK; TREATMENT OUTCOME;

ABO BLOOD-GROUP SYSTEM; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; BLOOD GROUP INCOMPATIBILITY; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLASMAPHERESIS; RISK; TRANSPLANTATION IMMUNOLOGY;

EID: 84865260325     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2012.700892     Document Type: Article

References (22)

1. Ichimaru N, Takahara S. Japan's experience with living-donor kidney transplantation across ABO barriers. Nature Clinical Practice Nephrology. 2008;4:682-692.
2. Genberg H, Kumlien G, Wennberg L, Berg U, Tydn G. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: A 3-year follow-up. Transplantation. 2008;85:1745-1754.
3. Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABOincompatible renal transplantation without splenectomy. Am J Transplant. 2004;4:1315-1322.
4. Gloor JM, Stegall MD. O incompatible kidney transplantation. Current opinion in nephrology and hypertension. 2007;16:529-534.
5. Tyden G, Donauer J, Wadstrom J, et al. Implementation of a protocol for ABO-incompatible kidney transplantation: A three-center experience with 60 consecutive transplantations. Transplantation. 2007;83:1153-1155.
6. Fuchinoue S, Ishii Y, Sawada T, et al. The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction. Transplantation. 2011;91:853-857.
7. Chung BH, Lee JY, Kang SH, et al. Comparison of clinical outcome between high and low baseline anti-ABO antibody titers in ABO-incompatible kidney transplantation. Ren Fail. 2011;33:150-158.
8. Tobian AA, Shirey RS, Montgomery RA, Tisch DJ, Ness PM, King KE. Therapeutic plasma exchange reduces ABO titers to permit ABO-incompatible renal transplantation. Transfusion. 2009;49:1248-1254.
9. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation. 2004;77:542-548.
10. Toki D, Ishida H, Horita S, Setoguchi K, Yamaguchi Y, Tanabe K. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. Transpl Int. 2009;22:447-454.
11. Shirakawa H, Ishida H, Shimizu T, et al. The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: A single-center experience. Clin Transplant. 2011;25:878-884.
12. Schroder C, Azimzadeh AM, Wu G, Price JO, Atkinson JB, Pierson RN. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol. 2003;12:19-28.
13. Lawrence C, Galliford JW, Willicombe MK, et al. Antibody removal before ABO-incompatible renal transplantation: How much plasma exchange is therapeutic? Transplantation. 2011;92:1129-1133.
14. Tobian AA, Shirey RS, Montgomery RA, et al. ABO antibody titer and risk of antibody-mediated rejection in ABOincompatible renal transplantation. Am J Transplant. 2010;10:1247-1253.
15. Grim SA, Pham T, Thielke J, et al. Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients. Clin Transplant. 2007;21:628-632.
16. Aikawa A, Ohara T, Arai K, et al. Clinical outcome and accommodation in ABO incompatible kidney transplantation. Clin Transplant. 2004;135-142.
17. Habicht A, Broker V, Blume C, et al. Increase of infectious complications in ABO-incompatible kidney transplant recipients a single centre experience. Nephrol Dial Transplant. 2011;26:4124-4131.
18. Choi BS, Shin MJ, Shin SJ, et al. Clinical significance of an early protocol biopsy in living-donor renal transplantation: Ten-year experience at a single center. Am J Transplant. 2005;5:1354-1360.
19. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant. 2008;8:753-760.
20. Setoguchi K, Ishida H, Shimmura H, et al. Analysis of renal transplant protocol biopsies in ABO-incompatible kidney transplantation. Am J Transplant. 2008;8:86-94.
21. Haas M, Segev DL, Racusen LC, et al. C4d deposition without rejection correlates with reduced early scarring in ABO-incompatible renal allografts. J Am Soc Nephrol. 2009;20:197-204.
22. Montgomery RA, Locke JE, King KE, et al. ABO incompatible renal transplantation: A paradigm ready for broad implementation. Transplantation. 2009;87:1246-1255.